Respiratory failure & ventilation
Amikacin pharmacokinetics after nebulization among intubated patients
Authors' conclusion
Nebulized amikacin achieved high pulmonary concentrations with minimal systemic exposure. Tracheal aspirate and plasma drug concentration were not significantly influenced by ventilation or nebulization conditions.
Study context
- Population
- Mechanically ventilated patients receiving 20 mg/kg amikacin by vibrating mesh nebulization498 tracheal aspirates · 602 plasma samples
- Participants
- 261 participants
Methodological detailsancillary study of a published randomised trial, population pharmacokinetic modelling
- Ancillary study of a published randomised trial
- Population pharmacokinetic modelling
Primary result
As reported in the abstract
Pulmonary and systemic amikacin pharmacokinetics
Median peak tracheal aspirate concentration (IQR 4935-9846 µg/g)
7269 µg/g
Median terminal half-life in tracheal aspirate (IQR 5.3-44.2 h)
7.6 h
Median peak plasma concentration (IQR 1.3-3.0 mg/L)
1.9 mg/L
Original publication
Amikacin pharmacokinetics after nebulization among intubated patients. Crit Care. Published 2 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →